Disclosure of Genotype Information to Reduce Caffeine Intake in Slow Metabolizers: Findings from a Randomized Controlled Trial on Personalized Dietary Interventions
Nutrients · 15.10.2025 · 17 (20) · 3236
DOI: 10.3390/nu17203236 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, online erschienen am 15.10.2025. Verfasst von Ewa Bulczak und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Nutrition and Dietetics, Poznań University of Life Sciences, 60-624 Poznań, Poland. Hauptthemen laut MEDLINE: Caffeine, Genotype, Cytochrome P-450 CYP1A2, Precision Medicine. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Polish Ministry of Science and Education.
Abstract (Originalsprache)
Background/Objectives: This study evaluated whether personalized nutrition (PN) advice combined with disclosure of genetic information leads to a greater reduction in caffeine consumption than PN advice alone in slow caffeine metabolizers in the short and long terms. Additionally, Ecological Momentary Assessment (EMA) was considered for its potential to improve dietary intake assessment.
Methods
In 2019–2021, 94 adults (aged 18–60 years, C allele carriers of rs762551 CYP1A2, consuming ≥ 200 mg/day caffeine), 63% of whom were women, participated in a twenty-week intervention. Participants were randomized to receive PN with genotype information (the intervention group, n = 55) or without it (the control group, n = 39). All participants were advised to limit caffeine intake to 100 mg/day. Caffeine intake was assessed using a food frequency questionnaire and a smartphones application. After three years caffeine intake was reassessed.
Results
After the intervention, caffeine consumption decreased (intervention group: 380.69 ± 217.58 to 153.73 ± 98.19 mg/day; control group: 394.44 ± 256.29 to 169.87 ± 85.70 mg/day; p < 0.01), with no group differences (p = 0.41). Three years later, a reduction (p < 0.01) was still observed in the intervention group, but the effect of time x group was insignificant. In total, 63% of the intervention group and 51% of the control group responded to at least three EMA prompts per day for at least three days.
Conclusions
PN seems to affect caffeine intake in the long term. However, including genotype information in PN is no more effective than receiving PN recommendations without genetic information. EMA’s effectiveness in large-scale nutritional research may be limited due to the relatively low response rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Human Nutrition and Dietetics, Poznań University of Life Sciences, 60-624 Poznań, Poland.
ORCID-Profile: Agata Chmurzynska
Förderung
- Polish Ministry of Science and Education
Zitieren
APA
Bulczak, E., & Chmurzynska, A. (2025). Disclosure of Genotype Information to Reduce Caffeine Intake in Slow Metabolizers: Findings from a Randomized Controlled Trial on Personalized Dietary Interventions. Nutrients, 17(20), 3236. https://doi.org/10.3390/nu17203236
Vancouver
Bulczak E, Chmurzynska A. Disclosure of Genotype Information to Reduce Caffeine Intake in Slow Metabolizers: Findings from a Randomized Controlled Trial on Personalized Dietary Interventions. Nutrients. 2025;17(20):3236. doi:10.3390/nu17203236
BibTeX
@article{Bulczak2025,
author = {Bulczak, Ewa and Chmurzynska, Agata},
title = {Disclosure of Genotype Information to Reduce Caffeine Intake in Slow Metabolizers: Findings from a Randomized Controlled Trial on Personalized Dietary Interventions},
journal = {Nutrients},
year = {2025},
volume = {17},
number = {20},
pages = {3236},
doi = {10.3390/nu17203236}
}
EUVIMED